Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.
Richard A AdamsDavid J FisherJanet GrahamJenny F SeligmannMatthew T SeymourRichard S KaplanEmma YatesMahesh K B ParmarSusan D RichmanPhilip QuirkeRachel ButlerEwan BrownFiona CollinsonStephen FalkHarpreet S WasanKai-Keen ShiuGary MiddletonLeslie SamuelRichard H WilsonLouise C BrownTimothy S Maughannull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Despite strong evidence of disease control with maintenance therapy, OS remains unaffected and FOCUS4-N provides additional evidence to support the use of treatment breaks as safe management alternatives for patients who are stable or responding to first-line treatment for mCRC. Capecitabine without bevacizumab may be used to extend PFS in the interval after 16 weeks of first-line therapy.